Core Viewpoint - Tongrentang Technology Company is advancing its core competitiveness from traditional practices to a modern scientific evidence system through significant research and development efforts since 2025 [1][7]. Group 1: Research and Development - The company is accelerating the development of new drugs, with the innovative traditional Chinese medicine Qishen Granules successfully entering Phase II clinical trials, aiming to provide safer and more effective treatment options for cardiovascular disease patients [3]. - Multiple clinical studies on well-known traditional Chinese medicine products have yielded fruitful results, including the completion of clinical research on Jinkui Shenqi Pill for "kidney yang deficiency with frequent night urination" and on Ganmao Qingre Granules for the effectiveness and safety in treating common colds [5]. Group 2: Scientific Evidence and Standards - The company has made significant breakthroughs in the pharmacological research of traditional formulas, such as the efficacy mechanism of Liuwei Dihuang Decoction for diabetic retinopathy and the real-world study of Yongshenghe Ejiao for tumor-related anemia, providing scientific insights into traditional medicine's role in modern disease treatment [5]. - The publication of 15 high-quality papers, including 3 in SCI journals, demonstrates the company's academic influence in traditional Chinese medicine and supports the establishment of industry technical standards [5]. Group 3: Industry Standards and Collaboration - Since 2025, the company has cooperated to release three group standards for traditional Chinese medicine, which have been officially implemented, and has been approved as the leading unit for a national pharmacopoeia standard improvement project [5][6]. - The company aims to establish the brand's reputation on solid modern scientific evidence, enhancing the market competitiveness of existing products and reserving growth momentum for the future [7].

Core Viewpoint - The company is actively transforming the traditional Chinese medicine industry through scientific and standardized practices, showcasing its capabilities in national strategic research and innovation [1][3]. Group 1: Research and Development Initiatives - The company has been approved as the leading unit for a national pharmacopoeia standard research project, focusing on the "Guiding Principles for the Determination of Biological Activity of Traditional Chinese Medicine" [1]. - The project aims to establish a "component-activity-efficacy" evaluation system to enhance quality control in traditional Chinese medicine, addressing common industry challenges [1][3]. - The innovative drug "Qi Shen Granules," a completely new type of traditional Chinese medicine, has successfully completed Phase II clinical production and is intended for chronic heart failure treatment [3]. Group 2: Quality Control and Standards - The company has implemented three new group standards for traditional Chinese medicine traceability in collaboration with the China Traditional Chinese Medicine Association [3]. - The company has achieved CNAS accreditation for its testing centers, indicating compliance with international standards and enhancing its competitive edge in both domestic and international markets [4][7]. - The focus on "zero defect quality management" is reinforced by high-quality inspection levels and ongoing improvements in laboratory standardization [4]. Group 3: Future Directions - The company plans to continue driving high-quality development through a dual-engine strategy of "quality" and "innovation," increasing resource investment to enhance its core competitiveness [7].